Etirinotecan Pegol ( NKTR ‐102) in Patients With Active Brain Metastases From Lung or Breast Cancer
Cancer Reports · 2025-09 · 8 (9)
DOI: 10.1002/cnr2.70330 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Cancer Reports, online erschienen am 28.08.2025. Verfasst von Seema Nagpal und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Division of Neuro-Oncology, Stanford University, Stanford, California, USA. Hauptthemen laut MEDLINE: Brain Neoplasms, Breast Neoplasms, Lung Neoplasms, Polyethylene Glycols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nektar Therapeutics.
Abstract (Originalsprache)
Background
Brain metastases are common in patients with lung and breast cancer and are associated with poor outcomes. While there is some intracranial activity with systemic therapies, most chemotherapies are minimally effective. Etirinotecan pegol (EP) is a PEGylated chemotherapy with favorable pharmacokinetics over irinotecan.
Methods
We conducted a phase 2 trial of EP in patients with previously treated metastatic non‐small cell lung cancer (NSCLC, n = 12), small cell lung cancer (SCLC, N = 3) and breast cancer (MBC, n = 12), having progressive brain metastases after brain‐directed radiotherapy (or refusal). The primary endpoint was a 25% or greater disease control rate, defined as CR, PR+SD, in the central nervous system (CNS) at 12 weeks; secondary endpoints included toxicity and systemic disease control.
Results
The CNS control rate at 12 weeks in NSCLC and MBC was 17% (two patients in each cohort) and 0% in SCLC. The median overall progression‐free survival for NSCLC was 2.7 months (95% CI: 1.3, 6.7) and MBC was 1.4 months (95% CI: 1.3, 6.9). The most common adverse events were diarrhea (48%), nausea (48%) and fatigue (26%). Six patient deaths occurred in this study. Dehydration/diarrhea (1) and neutropenic sepsis (3) from study treatment were at least possibly related to these deaths.
Conclusion
This study demonstrates that EP did not meet the threshold of clinical efficacy in patients with refractory CNS metastases from lung or breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Division of Neuro-Oncology, Stanford University, Stanford, California, USA.
- Department of Medicine, Division of Oncology, Stanford University, Stanford, California, USA.
- Quantitative Sciences Unit, School of Medicine, Stanford University, Stanford, California, USA.
- Fox Chase Cancer Center, Temple University, Philadelphia, Pennsylvania, USA.
- Stanford Health Care, Stanford, California, USA.
- UT Southwestern Medical Center, Dallas, Texas, USA.
ORCID-Profile: Joel W Neal
Förderung
- Nektar Therapeutics
Zitieren
APA
Nagpal, S., Nguyen, K. S., Bertrand, S., Cunanan, K. M., Padda, S. K., Pagtama, J. Y., Tisch, A. H., Coffey, G., Thomas, R. P., Sledge, G. W., Gruber, J., Telli, M. L., Pegram, M., Recht, L. D., Wakelee, H. A., Soltys, S. G., Massarweh, S. A., & Neal, J. W. (2025). Etirinotecan Pegol ( NKTR ‐102) in Patients With Active Brain Metastases From Lung or Breast Cancer. Cancer Reports, 8(9). https://doi.org/10.1002/cnr2.70330
Vancouver
Nagpal S, Nguyen KS, Bertrand S, Cunanan KM, Padda SK, Pagtama JY, et al. Etirinotecan Pegol ( NKTR ‐102) in Patients With Active Brain Metastases From Lung or Breast Cancer. Cancer Reports. 2025;8(9). doi:10.1002/cnr2.70330
BibTeX
@article{Nagpal2025,
author = {Nagpal, Seema and Nguyen, Kim-Son and Bertrand, Sophie and Cunanan, Kristen May and Padda, Sukhmani K and Pagtama, Judy Y and Tisch, Alison Holmes and Coffey, Gwen and Thomas, Reena P and Sledge, George W and Gruber, Joshua and Telli, Melinda L and Pegram, Mark and Recht, Lawrence D and Wakelee, Heather A and Soltys, Scott G and Massarweh, Suleiman A and Neal, Joel W},
title = {Etirinotecan Pegol ( NKTR ‐102) in Patients With Active Brain Metastases From Lung or Breast Cancer},
journal = {Cancer Reports},
year = {2025},
volume = {8},
number = {9},
doi = {10.1002/cnr2.70330}
}
EUVIMED